Additional Details

  • A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

    Clinical Site Partners
    Winter Park FL. 32789
    View Details

  • A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

    Renstar Medical Research
    Ocala FL. 34470
    View Details

  • A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

    Southeastern Research Center
    Winston-Salem NC. 27103
    View Details

  • A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

    Lowcountry Lung and Critical Care
    Charleston SC. 29406
    View Details

  • A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

    Newport Native MD, Inc.
    Newport Beach CA. 92663
    View Details

  • A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

    Clinical Site Partners, LCC
    Leesburg FL. 34748
    View Details

  • The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis

    University of Virginia
    Charlottesville VA. 22908
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

    Mayo Clinic
    Phoenix AZ. 85054
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

    MUSC Pulmonary Research
    Charleston SC. 29425
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

    Montefiore Medical Center
    Bronx NY. 10467
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

    Mayo Clinic
    Jacksonville FL. 32224
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

    Newport Native MD, Inc.
    Newport Beach CA. 92663
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

    Southeastern Research Center
    Winston-Salem NC. 27103
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Saint Petersburg FL. 33704
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Vancouver V5Z 1M9
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Los Angeles CA. 90033
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Hamilton L8N 4A6
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Wilmington NC. 28401
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Newport Beach CA. 92663
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Kissimmee FL. 34746
    View Details